David W Haas

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study

Catia Marzolini, Edward P Acosta, D. Clifford, 2004, AIDS.

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

Jack T Stapleton, Stuart Haber, David Heckerman, 2010, Science.

Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control.

Nicole Soranzo, Manuel A. R. Ferreira, Sarah E Medland, 2010, American journal of human genetics.

Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.

Joshua Chen, D. Haas, J. Condra, 2003, The Journal of infectious diseases.

Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants

Marylyn D Ritchie, Gene D Morse, Benjamin J. Grady, 2012, Pharmacogenetics and genomics.

Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study

Marshall Summar, Marylyn D Ritchie, Robert W Shafer, 2005, AIDS.

Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study.

Alison A Motsinger, Marylyn D Ritchie, Richard T D'Aquila, 2006, The Journal of infectious diseases.

A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control

David Heckerman, Jacques Fellay, Christoph Lippert, 2013, eLife.